Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Utah for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Utah only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Utah (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Joseph Te (NPI 1700946423)

Field	Value
Entity Type	Individual
Organization	Joseph Te
Address	2019 E Riverside Dr Ste A200
City	St George
State	UT
ZIP	84790
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	December 11, 2006

Payer Source	Total Paid
Medicare	$1.6M
Medicaid	$0

Key Findings

JOSEPH TE (Hematology & Oncology Physician, ST GEORGE UT) is an established Medicare-focused oncology practice with Total Medicare revenue of $1.6M and no Medicaid billing on file. The provider’s top three Medicare codes (J9271, J0897, 99214) account for 63.7% of Medicare revenue, indicating a revenue profile concentrated in a small set of high-impact therapies and E/M services.

The single largest revenue driver is J9271 (pembrolizumab) with $430.3K in revenue (28.0% of the provider's Medicare revenue); this volume ranks #1181 of 1841 nationally (36th percentile; typical, unremarkable volume). That placement suggests the provider administers significant immunotherapy but at a pace that is consistent with many peers rather than being an outsized national center for pembrolizumab.

J0897 (denosumab) is the second-largest contributor at $402.8K (26.2% of Medicare revenue) and ranks #221 of 10057 nationally (98th percentile; notably above typical national volume). This unusually high percentile for denosumab implies a strong focus on bone-directed therapy or supportive care for patients with metastatic bone disease relative to national peers.

99214 E/M visits account for $146.8K (9.5% of Medicare revenue) and the provider ranks #2900 of 479517 nationally (99th percentile; extreme outlier). The extreme outlier classification for 99214 signals substantial office-based follow-up volume for established patients, reflecting either a high patient panel size, frequent chronic-care visits, or a clinic model that emphasizes longitudinal management.

Beyond the top three codes, the provider records elevated national standing on several infusion- and therapy-related codes: Q5119 ($94.3K, 6.1%) ranks #22 of 335 (94th percentile; typical), J2506 ($69.3K, 4.5%) ranks #53 of 586 (91th percentile; typical), and 96413 ($50.3K, 3.3%) ranks #562 of 7514 (92th percentile; notably above typical). These rank patterns, together with codes like 96365, 96367, G0498, 96417 and multiple chemotherapy add-ons, indicate an active infusion service line with routine chemotherapy administration at the practice.

The practice’s procedural and laboratory mix includes on-site monitoring and diagnostics—notable entries include 85025 ($18.1K, 1.2%), 36415 ($15.2K, 1.0%), and 80053 ($15K, 1.0%)—which supports an operational model that combines infusion therapy with in-office phlebotomy and lab panels. The presence of many infusion administration and add-on chemotherapy codes (e.g., 96415, 96417) further supports a clinic that delivers multi-agent regimens in outpatient sessions.

Payer concentration is pronounced: the practice is effectively single-payer with Medicare-only billing on file (Total Medicare revenue $1.6M and no Medicaid billing on file). That concentration increases operational exposure to Medicare reimbursement policy and utilization shifts, particularly for high-revenue drugs such as J9271 and J0897 which together represent 54.2% of Medicare revenue by the individual shares provided.

The provider’s NPI was enumerated on 2006-12-11 (~20 years ago), indicating an established tenure in the market. Combined with the concentrated revenue profile (top three codes = 63.7%) and multiple high-percentile code rankings (including an extreme outlier for 99214), the data portray a mature, clinic-based oncology practice with significant infusion volume and tight dependence on a small set of high-value therapies and frequent E/M visits.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

69 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	10,010	$40	$430.3K
J0897	Injection, denosumab, 1 mg	22,380	$20	$402.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,610	$90	$146.8K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	4,100	$20	$94.3K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	890	$80	$69.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	890	$60	$54.9K
J1439	Injection, ferric carboxymaltose, 1 mg	53,250	$1	$53.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	540	$90	$50.3K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	330	$130	$43.4K
Q5106	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	6,970	$10	$41.8K

Showing 1–10 of 69

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 69 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Utah Distribution

Joseph Te — 14 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Utah

Full comparison — all codes billed, vs. state median

69 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	10	10,010	$40	$510.2K
J3490	12	30	80	$1,690	$199.5K
Q5119	1	10	3,700	$20	$84.2K
J2506	1	10	890	$80	$69.5K
J0897	2	70	1,920	$20	$67.2K
Q5106	1	10	6,970	$10	$42.9K
J9217	4	30	140	$130	$23.8K
J1439	1	20	15,750	$1	$17.5K
96413	2	50	100	$90	$13.8K
96401	6	20	140	$50	$13.7K

Showing 1–10 of 69

Related Providers

Other providers that share a Tax Identification Number (TIN) with Joseph Te, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Revere Health PC	UT	Multi-Specialty Clinic/Center	$0	$24M
Brandt Esplin	UT	Hematology & Oncology Physician	$1.1M	$0
Jamison Jones	UT	Cardiovascular Disease Physician	$1M	$0
Steven Wallentine	UT	Hematology & Oncology Physician	$1M	$7.6K
Robert Dowse	UT	Pediatrics Physician	$0	$867K
David Slade	UT	Ophthalmology Physician	$651.1K	$0
Marc Nuttall	UT	Hematology & Oncology Physician	$549.1K	$580
Leslee Adams	UT	Family Nurse Practitioner	$513.4K	$0
David Cragun	UT	Cardiovascular Disease Physician	$465.1K	$940
James Macdonald	UT	Dermatology Physician	$415.3K	$26.5K

Nearby Providers

Other providers in the same ZIP code as Joseph Te, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ihc Health Services, Inc.	UT	General Acute Care Hospital	$0	$65.8M
Southwest Utah Community Health Center	UT	Federally Qualified Health Center (FQHC)	$0	$7.3M
Zion Eye Institute, Inc	UT	Ambulatory Surgical Clinic/Center	$6.1M	$19.7K
Summit Behavior Services	UT	Counselor	$0	$5.4M
Ihc Health Services Inc	UT	Multi-Specialty Clinic/Center	$0	$4.4M
Ron Lord	UT	Ophthalmology Physician	$3.2M	$0
Joshua Carlson	UT	Retina Specialist (Ophthalmology) Physician	$2.6M	$0
St George Surgical Center LP	UT	Ambulatory Surgical Clinic/Center	$2.5M	$0
Coral Desert Surgery Center LLC	UT	Ambulatory Surgical Clinic/Center	$2.5M	$17.8K
Ihc Health Services Inc	UT	Clinical Medical Laboratory	$2.4M	$42.7K

Joseph Te — Billing Profile & Reimbursement Data

Sign up for Joseph Te — Billing Profile & Reimbursement Data policy alerts

Joseph Te — Billing Profile & Reimbursement Data

Sign up for Joseph Te — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References